Viridian Therapeutics Inc美股招股说明书(2025-10-23版)

PROSPECTUS SUPPLEMENT(To Prospectus dated September5, 2025) 11,425,000 Shares of Common Stock We are offering 11,425,000 shares of our common stock, par value $0.01 per share (“common stock”). Our common stock is traded on The Nasdaq Capital Market under the symbol “VRDN.” On October21, 2025, the last reported sale priceper share of our common stock was $24.02. (1)See “Underwriting” beginning onpageS-23of this prospectus supplement for additional information regarding underwriting compensation. We have granted the underwriters an option to purchase up to an additional 1,713,750 shares of our common stock from us, at the publicoffering price, less underwriting discounts and commissions, within 30days of the date of this prospectus supplement. Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertaintiesdescribed under the heading “Risk Factors” onpageS-6of this prospectus supplement and in the accompanying prospectus,as well as those contained in the other documents that are incorporated by reference and any related free writing prospectus.You should carefully read this entire prospectus supplement and the accompanying prospectus, including any informationincorporated by reference, before deciding whether to purchase shares of our common stock. Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved ofthese securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Anyrepresentation to the contrary is a criminal offense. The underwriters expect to deliver the shares of common stock on or about October23, 2025. Stifel LeerinkPartners Jefferies Wedbush PacGrow October21, 2025 Table of Contents Table of Contents Prospectus Supplement Prospectus Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This prospectus supplement and the accompanying prospectus form part of a registration statement on FormS-3(FileNo.333-290056)that wefiled with the U.S. Securities and Exchange Commission (the “SEC”) on September5, 2025, as a “well-known seasoned issuer” as defined inRule 405 under the Securities Act of 1933, as amended (the “Securities Act”), utilizing a “shelf” registration process. Under this shelf registrationprocess, we may, from time to time, sell common stock and other securities, including in this offering. This document contains two parts. The firstpart consists of this prospectus supplement, which provides you with specific information about this offering. The second part consists of theaccompanying prospectus, which provides more general information, some of which may not apply to this offering. Generally, when we refer onlyto the “prospectus,” we are referring to both parts combined. This prospectus supplement may add, update or change information contained in theaccompanying prospectus. To the extent that any statement we make in this prospectus supplement is inconsistent with statements made in theaccompanying prospectus, or any documents incorporated by reference, the statements made in this prospectus supplement will be deemed tomodify or supersede those made in the accompanying prospectus, including the documents incorporated by reference therein. Information in anydocument we subsequently file that is incorporated by reference shall modify or supersede the information in this prospectus supplement, theaccompanying prospectus and documents incorporated by reference prior to such subsequent filing. It is important for you to read and considerall information contained in this prospectus supplement and the accompanying prospectus, including the documents we have referred you to inthe section entitled “Where You Can Find More Information” below in this prospectus supplement. We are responsible for the information contained and incorporated by reference in this prospectus supplement, the accompanying prospectusand in any free writing prospectus that we have authorized for use in connection with this offering. We have not authorized anyone to give youany other information, and we take no responsibility for any other information that others may give you. We are not making offers to sell thesecurities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation isnot qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. The information contained and incorporated by referencein this prospectus supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection withthis offering speaks only as of the date of this document, unless the information specifically indicates that another date applies. Neither thedelivery of this prospectus supplement, the accompanying prospectus or any free writing prospectus that we have authorized for use inconnection with this offer